Join Benitec Biopharma for a virtual R&D Day, featuring two key opinion leaders who will discuss the clinical symptoms and the natural history of oculopharyngeal muscular dystrophy (OPMD), a rare genetic muscle disorder. The key opinion leaders will also review the clinical and radiographic methods employed to evaluate disease progression and discuss the current treatment landscape for patients diagnosed with OPMD.

• Bernard Brais, MDCM, PhD – Professor, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University Health Centre
• Emily Plowman, PhD, CCC-SLP, FASHA – Professor, Department of Otolaryngology – Head and Neck Surgery, The Ohio State University College of Medicine

The event will focus on the Company’s clinical development program for its investigational gene therapy agent BB-301, which is currently being evaluated in a Phase 1b/2a clinical trial for the treatment of OPMD-derived dysphagia. Key areas of focus will include discussions of clinical, radiographic, and subject-reported assessments of disease progression, clinical study design, and the specific primary and secondary endpoints that will be used to quantify subject improvement over the course of the BB-301 clinical development program.

A live question and answer session will follow the formal presentations.